Gilead Sciences Stock Fundamentals
| GILD34 Stock | BRL 287.56 4.47 1.58% |
Gilead Sciences fundamentals help investors to digest information that contributes to Gilead Sciences' financial success or failures. It also enables traders to predict the movement of Gilead Stock. The fundamental analysis module provides a way to measure Gilead Sciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gilead Sciences stock.
Gilead |
Gilead Sciences Company Profit Margin Analysis
Gilead Sciences' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Gilead Sciences Profit Margin | 0.17 % |
Most of Gilead Sciences' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gilead Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Gilead Sciences has a Profit Margin of 0.1683%. This is 101.5% lower than that of the Healthcare sector and 98.92% lower than that of the Drug Manufacturers - Major industry. The profit margin for all Brazil stocks is 113.25% lower than that of the firm.
Gilead Sciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Gilead Sciences's current stock value. Our valuation model uses many indicators to compare Gilead Sciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gilead Sciences competition to find correlations between indicators driving Gilead Sciences's intrinsic value. More Info.Gilead Sciences is rated # 4 in return on equity category among its peers. It is rated # 3 in return on asset category among its peers reporting about 0.48 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Gilead Sciences is roughly 2.07 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Gilead Sciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Gilead Sciences' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Gilead Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gilead Sciences' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gilead Sciences could also be used in its relative valuation, which is a method of valuing Gilead Sciences by comparing valuation metrics of similar companies.Gilead Sciences is rated # 4 in profit margin category among its peers.
Gilead Fundamentals
| Return On Equity | 0.22 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.40 % | |||
| Current Valuation | 686.18 B | |||
| Shares Outstanding | 2.49 B | |||
| Price To Earning | 28.35 X | |||
| Price To Book | 5.30 X | |||
| Price To Sales | 21.27 X | |||
| Revenue | 27.28 B | |||
| Gross Profit | 21.62 B | |||
| EBITDA | 6.75 B | |||
| Net Income | 4.59 B | |||
| Cash And Equivalents | 28.36 B | |||
| Cash Per Share | 22.39 X | |||
| Total Debt | 25.18 B | |||
| Debt To Equity | 117.00 % | |||
| Current Ratio | 3.76 X | |||
| Book Value Per Share | 17.01 X | |||
| Cash Flow From Operations | 9.07 B | |||
| Earnings Per Share | 9.63 X | |||
| Price To Earnings To Growth | 0.71 X | |||
| Number Of Employees | 31 | |||
| Beta | 0.41 | |||
| Market Capitalization | 572.2 B | |||
| Total Asset | 63.17 B | |||
| Z Score | 13.2 | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 63.17 B | |||
| Last Dividend Paid | 2.92 |
About Gilead Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gilead Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gilead Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gilead Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. GILEAD DRN operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 11000 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Gilead Stock
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.